Sign in
Active, not recruitingPhase 3

Treat-CMV

Key facts

Who runs it
UZ Leuven
Where
Belgium7 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
112 people, planned
Started
19 Jun 2024
Expected to end
1 Jul 2031
Type of study
Interventional
Record updated
13 March 2025

Who can take part

Age
Up to 64 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • 18 years or older
  • Proven first trimester primary CMV infection

Who cannot take part

  • Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
  • Participant has a history of kidney function problems, liver function problems, immunocomprimised
  • Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to investigate the effectivity of valaciclovir to prevent vertical CMV transmission during pregnancy in first trimester primary maternal CMV infections.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Congenital CMV treated with valaciclovir during pregnancy: a prospective cohort study
Record updated
13 March 2025